| Literature DB >> 35576512 |
Alejandra Mendoza-Pérez1,2, Marlen Vitales-Noyola1, Larisa González-Baranda1,3, Crisol Álvarez-Quiroga1, Berenice Hernández-Castro1,2, Adriana Monsiváis-Urenda1,2, Lourdes Baranda1,2,3, Perla Niño-Moreno1, Gilberto Hurtado3, Raquel Sánchez-Gutiérrez1,2, Roberto González-Amaro1,2.
Abstract
A low-grade inflammatory phenomenon is a feature of overweight and metabolic syndrome. The involvement of a pro-inflammatory Th17 lymphocyte subset and the CD69+ T regulatory (Treg) cell subtype in patients with metabolic dysfunction associated with or without overweight has not been fully elucidated. The aim of this study was to perform a quantitative and functional analysis of pathogenic Th17 lymphocytes and CD69+ Treg cells in patients with metabolic dysfunction (insulin resistance and dyslipidemia). The number of pathogenic Th17 cells and the levels and function of CD69+ Treg cells were analyzed in blood samples from individuals with metabolic dysfunction, associated with or without overweight. Pathogenic and non-pathogenic Th17 lymphocytes as well as Th22 cells were determined by eight-color flow cytometry analysis, whereas the levels and suppressive function of CD69+ Treg cells were also analyzed by multiparametric flow cytometry. We detected increased levels of pro-inflammatory Th17 pathogenic cells and Th22 lymphocytes in overweight unhealthy individuals (P < 0.001, compared to normal weight healthy). Conversely, diminished numbers of CD69+ Treg lymphocytes were observed in metabolically unhealthy individuals, with or without overweight. Likewise, the immunosuppressive function of CD69+ Treg cells was also defective in these patients. The increased levels of pathogenic Th17 cells along with a diminished number and function of CD69+ Treg lymphocytes may significantly contribute to the low-grade inflammatory phenomenon of metabolically unhealthy patients.Entities:
Keywords: immune regulation; interleukin-17; lymphocytes; metabolic syndrome
Mesh:
Year: 2022 PMID: 35576512 PMCID: PMC9307236 DOI: 10.1093/cei/uxac051
Source DB: PubMed Journal: Clin Exp Immunol ISSN: 0009-9104 Impact factor: 5.732